The New Biomarkers Pathologists Need to Know for Precision Therapy in Lung Cancer

Join us for this dynamic live-stream Webinar featuring Nathan Pennell, MD, PhD, a medical oncologist, and Laura J. Tafe, MD, a molecular pathologist, to get up to date on testing for new and emerging predictive biomarkers critical to optimal management of advanced NSCLC.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.

Agenda

  • The Why and Who: Overview of Newly Available and Emerging Biomarkers in Lung Cancer Therapy
    • New and emerging predictive biomarkers for targeted therapies
    • Interpreting biomarker assay results and how results should impact therapeutic planning and/or clinical trial enrollment
    • Predictive biomarkers for immune checkpoint inhibitor therapy
    • Current status of testing: How are we doing?
  • The How: Evidence-Based Testing Strategies to Detect Appropriate Fusions and Mutations
    • Best practices from sample collection to test result
    • Strategies to ensure appropriate testing for all patients who should be tested
  • Faculty Discussion and Audience Question and Answer Session: Clinical Pearls and Future Directions in Molecular Profiling/Precision Medicine in Lung Cancer

Faculty

Faculty
Nathan Pennell, MD, PhD

Associate Professor
Director,
Cleveland Clinic Lung Cancer Medical Oncology Program
Department of Hematology and Medical Oncology
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio

Faculty
Laura J. Tafe, MD

Goal Statement
The goal of this activity is to improve the knowledge, competence, and performance of learners to assess new and emerging biomarkers and planning individualized treatment for patient with lung cancer.

Target Audience
This program is intended for physicians, pathologists, and other healthcare providers who care for patients with lung cancer.

Learning Objectives
At the conclusion of this activity, learners should be able to:

  • Apply new and emerging predictive biomarkers to guide therapeutic decisions in patients with lung cancer
  • Summarize the available data and expert recommendations to determine which biomarkers should be tested in your patients with lung cancer
  • Evaluate the available next-generation sequencing and comprehensive genomic profiling diagnostic assays
  • Identify patients eligible to enroll on important ongoing clinical trials based on molecular testing of their tumor

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation 

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

American Board of Pathology Continuing Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Lifelong Learning (Part II) and Self-Assessment Module (SAM) point in the American Board of Pathology’s Maintenance of Certification (MOC) Program. Participants will earn MOC point equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification (formerly Maintenance of Certification or MOC) credit.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.